Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

In Vitro p24 Antigen-Stimulated Lymphocyte Proliferation and β-Chemokine Production in Human Immunodeficiency Virus Type 1 (HIV-1)-Seropositive Subjects after Immunization with an Inactivated gp120-Depleted HIV-1 Immunogen (Remune)

In Vitro p24 Antigen-Stimulated Lymphocyte Proliferation and β-Chemokine Production in Human... In Vitro p24 Antigen-Stimulated Lymphocyte Proliferation and β-Chemokine Production in Human Immunodeficiency Virus Type 1 (HIV-1)-Seropositive Subjects after Immunization with an Inactivated gp120-Depleted HIV-1 Immunogen (Remune) Ronald B. Moss 1 , * , Mark R. Wallace 2 , Paola Lanza 1 , Wieslawa Giermakowska 1 , Fred C. Jensen 1 , Georgia Theofan 1 , Carolyn Chamberlin 2 , Steven P. Richieri 1 , and Dennis J. Carlo 1 The Immune Response Corporation, Carlsbad, 1 and Division of Infectious Diseases, U.S. Naval Medical Center, San Diego, 2 California ABSTRACT We examined the effect of immune stimulation by a human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) compared to a non-HIV vaccine (influenza) on HIV-1-specific immune responses in HIV-1-seropositive subjects. HIV-1 p24 antigen-stimulated lymphocyte proliferation was not augmented after immunization with the influenza vaccine. In contrast, subjects increased their lymphocyte proliferative responses to p24 antigen after one immunization with HIV-1 immunogen (Remune) (gp120-depleted inactivated HIV-1 in incomplete Freund’s adjuvant). Furthermore, p24 antigen-stimulated β-chemokine production (RANTES, MIP-1α, MIP-1β) was also augmented after immunization with the HIV-1 immunogen but not influenza vaccine. Taken together, these results suggest that in this cohort, HIV-specific immune responses to p24 antigen can be augmented after immunization with an HIV-1 immunogen. The ability to upregulate immune responses to the more conserved core proteins may have important implications in the development of immunotherapeutic interventions for HIV-1 infection. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Vaccine Immunology American Society For Microbiology

In Vitro p24 Antigen-Stimulated Lymphocyte Proliferation and β-Chemokine Production in Human Immunodeficiency Virus Type 1 (HIV-1)-Seropositive Subjects after Immunization with an Inactivated gp120-Depleted HIV-1 Immunogen (Remune)

In Vitro p24 Antigen-Stimulated Lymphocyte Proliferation and β-Chemokine Production in Human Immunodeficiency Virus Type 1 (HIV-1)-Seropositive Subjects after Immunization with an Inactivated gp120-Depleted HIV-1 Immunogen (Remune)

Clinical and Vaccine Immunology , Volume 5 (3): 308 – May 1, 1998

Abstract

In Vitro p24 Antigen-Stimulated Lymphocyte Proliferation and β-Chemokine Production in Human Immunodeficiency Virus Type 1 (HIV-1)-Seropositive Subjects after Immunization with an Inactivated gp120-Depleted HIV-1 Immunogen (Remune) Ronald B. Moss 1 , * , Mark R. Wallace 2 , Paola Lanza 1 , Wieslawa Giermakowska 1 , Fred C. Jensen 1 , Georgia Theofan 1 , Carolyn Chamberlin 2 , Steven P. Richieri 1 , and Dennis J. Carlo 1 The Immune Response Corporation, Carlsbad, 1 and Division of Infectious Diseases, U.S. Naval Medical Center, San Diego, 2 California ABSTRACT We examined the effect of immune stimulation by a human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) compared to a non-HIV vaccine (influenza) on HIV-1-specific immune responses in HIV-1-seropositive subjects. HIV-1 p24 antigen-stimulated lymphocyte proliferation was not augmented after immunization with the influenza vaccine. In contrast, subjects increased their lymphocyte proliferative responses to p24 antigen after one immunization with HIV-1 immunogen (Remune) (gp120-depleted inactivated HIV-1 in incomplete Freund’s adjuvant). Furthermore, p24 antigen-stimulated β-chemokine production (RANTES, MIP-1α, MIP-1β) was also augmented after immunization with the HIV-1 immunogen but not influenza vaccine. Taken together, these results suggest that in this cohort, HIV-specific immune responses to p24 antigen can be augmented after immunization with an HIV-1 immunogen. The ability to upregulate immune responses to the more conserved core proteins may have important implications in the development of immunotherapeutic interventions for HIV-1 infection.

Loading next page...
 
/lp/american-society-for-microbiology/in-vitro-p24-antigen-stimulated-lymphocyte-proliferation-and-chemokine-zDB4Yo8juP

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Society For Microbiology
Copyright
Copyright © 1998 by the American society for Microbiology.
ISSN
1556-6811
eISSN
1556-679X
Publisher site
See Article on Publisher Site

Abstract

In Vitro p24 Antigen-Stimulated Lymphocyte Proliferation and β-Chemokine Production in Human Immunodeficiency Virus Type 1 (HIV-1)-Seropositive Subjects after Immunization with an Inactivated gp120-Depleted HIV-1 Immunogen (Remune) Ronald B. Moss 1 , * , Mark R. Wallace 2 , Paola Lanza 1 , Wieslawa Giermakowska 1 , Fred C. Jensen 1 , Georgia Theofan 1 , Carolyn Chamberlin 2 , Steven P. Richieri 1 , and Dennis J. Carlo 1 The Immune Response Corporation, Carlsbad, 1 and Division of Infectious Diseases, U.S. Naval Medical Center, San Diego, 2 California ABSTRACT We examined the effect of immune stimulation by a human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) compared to a non-HIV vaccine (influenza) on HIV-1-specific immune responses in HIV-1-seropositive subjects. HIV-1 p24 antigen-stimulated lymphocyte proliferation was not augmented after immunization with the influenza vaccine. In contrast, subjects increased their lymphocyte proliferative responses to p24 antigen after one immunization with HIV-1 immunogen (Remune) (gp120-depleted inactivated HIV-1 in incomplete Freund’s adjuvant). Furthermore, p24 antigen-stimulated β-chemokine production (RANTES, MIP-1α, MIP-1β) was also augmented after immunization with the HIV-1 immunogen but not influenza vaccine. Taken together, these results suggest that in this cohort, HIV-specific immune responses to p24 antigen can be augmented after immunization with an HIV-1 immunogen. The ability to upregulate immune responses to the more conserved core proteins may have important implications in the development of immunotherapeutic interventions for HIV-1 infection.

Journal

Clinical and Vaccine ImmunologyAmerican Society For Microbiology

Published: May 1, 1998

There are no references for this article.